Loading...
SYRE logo

Spyre Therapeutics, Inc.NasdaqGS:SYRE Stock Report

Market Cap US$6.3b
Share Price
US$73.48
US$95.2
22.8% undervalued intrinsic discount
1Y380.9%
7D-0.8%
1D
Portfolio Value
​
View

Spyre Therapeutics, Inc.

NasdaqGS:SYRE Stock Report

Market Cap: US$6.3b

Spyre Therapeutics (SYRE) Stock Overview

A clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. More details

SYRE fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Rewards

Analysts in good agreement that stock price will rise by 29.6%

Risk Analysis

Earnings are forecast to decline by an average of 17% per year for the next 3 years

Makes less than USD$1m in revenue ($0)

Shareholders have been substantially diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years


SYRE Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Spyre Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Spyre Therapeutics
Historical stock prices
Current Share PriceUS$73.48
52 Week HighUS$78.80
52 Week LowUS$13.93
Beta3.13
1 Month Change2.21%
3 Month Change70.84%
1 Year Change380.89%
3 Year Change2,196.25%
5 Year Change-55.26%
Change since IPO-75.49%

Recent News & Updates

Recent updates

Seeking Alpha • Mar 17

Spyre: 'Strong Buy' As UC Program Moves Along And Q3 2026 RA Data Looms

Summary Spyre Therapeutics, Inc. receives a Strong Buy rating, driven by positive phase 1 data and robust pipeline progress in IBD and rheumatic diseases. SPY001 demonstrated a half-life 4x greater than ENTYVIO, supporting quarterly or twice-yearly dosing for ulcerative colitis in the ongoing phase 2 SKYLINE trial. Accelerated recruitment in the phase 2 SKYWAY RA sub-study brings the anti-TL1A SPY072 data readout forward to Q3 2026, enhancing SYRE's near-term catalysts. SYRE's $757M cash position funds operations into H2 2028, supporting multiple clinical milestones and reducing near-term financing risk. Read the full article on Seeking Alpha
Analysis Article • Jul 15

Companies Like Spyre Therapeutics (NASDAQ:SYRE) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Mar 04

Spyre Therapeutics: Targeting The Future Of IBD Treatment

Summary Spyre Therapeutics is emerging as a key player in inflammatory bowel disease, with a focus on pathway-specific monoclonal antibodies for superior disease control. The company has a healthy balance sheet with $603.1 million in cash, providing a four-year runway at its current burn rate. SYRE's innovative combination therapy approach targets multiple inflammatory pathways, aiming for better efficacy and long-term disease control in ulcerative colitis. Upcoming clinical trials in 2025 and 2026 are critical for validating Spyre's therapies and determining its potential to shift the treatment paradigm. Read the full article on Seeking Alpha
Seeking Alpha • Dec 12

Spyre Therapeutics: Different Name, Same Tune

Summary Today, we take an in-depth look at Spyre Therapeutics, Inc., which has promising assets in early-stage development, including SPY001, SPY002, and SPY003. The company changed its name from Aeglea BioTherapeutics, Inc. late last year, and thanks to a recent capital raise, is extremely well funded. Analyst firms also appear optimistic around the company's developmental approach. An analysis of SYRE stock follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Oct 01

Spyre: Extended Half-Life Tech To Become Differentiating Factor For IBD Targeting

Summary Spyre Therapeutics, Inc. interim data from the phase 1 study, using SPY001 in healthy volunteers, is expected by the end of 2024. SPY001 is an a4b7 inhibitor being developed to target IBD like Crohn's Disease and Ulcerative Colitis. The Crohn's Disease treatment market is projected to reach a value of $17.80 billion by 2033. The global Ulcerative Colitis market is expected to be $10.79 billion by 2030. Read the full article on Seeking Alpha
Seeking Alpha • Aug 18

Aeglea stock jumps ~58% after hours on European nod for enzyme pegzilarginase

Aeglea BioTherapeutics (NASDAQ:AGLE) on Thursday said Europe's drug regulator had validated the company's marketing authorization application for enzyme pegzilarginase for the treatment of Arginase 1 deficiency. Shares of the micro-cap clinical-stage biotech soared 57.5% to $0.80 in postmarket trading. The application was submitted by AGLE's commercialization partner in Europe and Middle East, Immedica Pharma, AGLE said in a statement. Arginase 1 deficiency is a rare, inherited disorder in which there is complete or partial lack of the enzyme arginase in the liver and red blood cells. Aeglea (AGLE) earlier in Aug. reported a mixed set of Q2 results.
Seeking Alpha • Aug 04

Aeglea BioTherapeutics GAAP EPS of -$0.27 beats by $0.04, revenue of $0.63M misses by $0.08M

Aeglea BioTherapeutics press release (NASDAQ:AGLE): Q2 GAAP EPS of -$0.27 (vs. -0.10 Y/Y)  beats by $0.04. Revenue of $0.63M (-95.4% Y/Y) misses by $0.08M. Shares +5.07% PM.
Seeking Alpha • Dec 07

Aeglea Presents Itself As Buy Opportunity After Latest Data Causes Stock To Trade Lower

Aeglea achieved primary endpoint in reducing arginine levels with its drug pegzilarginase for ARG1-D, which in turn reduced ammonia in the blood plasma, by an average of 80%. BLA filing of pegzilarginase for patients with ARG1-D is expected to occur in 1st half of 2022. Additional results from the phase 3 PEACE study, using pegzilarginase for patients with ARG1-D, are expected to be released at an upcoming medical meeting and in peer-reviewed medical journals. The company will also submit a regulatory application for pegzilarginase for ARG1-D, with its partner Immedica Pharma, to Europe and other Middle East countries in 2022.

Shareholder Returns

SYREUS BiotechsUS Market
7D-0.8%1.3%1.8%
1Y380.9%33.0%28.4%

Return vs Industry: SYRE exceeded the US Biotechs industry which returned 33% over the past year.

Return vs Market: SYRE exceeded the US Market which returned 28.4% over the past year.

Price Volatility

Is SYRE's price volatile compared to industry and market?
SYRE volatility
SYRE Average Weekly Movement10.6%
Biotechs Industry Average Movement10.8%
Market Average Movement7.2%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market3.0%

Stable Share Price: SYRE has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: SYRE's weekly volatility (11%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2013112Cameron Turtlewww.spyre.com

Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn’s disease); and SPY002 and SPY072 – anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also developing SPY003, a clinical-stage program, which is in phase-2 clinical stage designed to bind to interleukin 23 (IL-23); SPY120, a combination of anti-a4ß7 and anti-TL1A mAbs; SPY130, a combination anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination anti-TL1A and anti-IL-23 mAbs.

Spyre Therapeutics, Inc. Fundamentals Summary

How do Spyre Therapeutics's earnings and revenue compare to its market cap?
SYRE fundamental statistics
Market capUS$6.26b
Earnings (TTM)-US$148.70m
Revenue (TTM)n/a
0.0x
P/S Ratio
-42.9x
P/E Ratio

Is SYRE overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SYRE income statement (TTM)
RevenueUS$0
Cost of RevenueUS$190.44m
Gross Profit-US$190.44m
Other Expenses-US$41.74m
Earnings-US$148.70m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)-1.71
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did SYRE perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/29 21:56
End of Day Share Price 2026/05/29 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Spyre Therapeutics, Inc. is covered by 24 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Colleen KusyBaird
Mayur SomaiyaBMO Capital Markets Equity Research
Julian HarrisonBTIG